Product Description
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00333502)
Mechanisms of Action: TOP1 Inhibitor, HIF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Double Point Ventures
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma|Prostate Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Squamous Cell Carcinoma|Gastrointestinal Cancer
Phase 1: Oncology Solid Tumor Unspecified|Renal Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02648711 |
CRLX101-102 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2017-10-17 |
2019-03-20 |
Treatments |
|
NCT01625936 |
UPCC 02812 | P1 |
Completed |
Renal Cell Carcinoma |
2017-07-01 |
2023-03-30 |
Primary Endpoints|Treatments |
|
NCT03531827 |
18-C-0096 | P2 |
Terminated |
Prostate Cancer |
2021-05-15 |
2022-07-13 |
Patient Enrollment|Primary Endpoints |
|
NCT02389985 |
CRLX101-209 | P2 |
Terminated |
Ovarian Cancer |
2018-06-04 |
2019-03-20 |
Treatments |
|
NCT01652079 |
NCT01652079 | P2 |
Completed |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2018-03-01 |
2019-03-19 |
Treatments |
|
NCT02010567 |
LCCC 1315 | P2 |
Terminated |
Colorectal Cancer |
2016-09-16 |
24% |
2020-11-04 |
Primary Endpoints|Study Completion Date|Trial Status |
NCT02187302 |
Investigator's Choice | P2 |
Completed |
Renal Cell Carcinoma |
2016-07-01 |
2019-03-20 |
Treatments |
|
NCT01612546 |
NCI-2012-00893 | P2 |
Completed |
Adenocarcinoma|Esophageal Cancer|Squamous Cell Carcinoma|Gastrointestinal Cancer |
2015-01-15 |
2024-11-27 |
Primary Endpoints |
|
NCT01380769 |
CRLX-002 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2013-02-01 |
2019-03-19 |